Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Colorectal Neoplasms 2Uterine Cervical Neoplasms 1Solid Tumor 1Recurrence 1Nasopharyngeal Carcinoma 1Carcinoma, Renal Cell 1

Interventions

Cisplatin 22Radiotherapy, Intensity-Modulated 12Fluorouracil 9Gemcitabine 7Docetaxel 7Cetuximab 5Capecitabine 5pembrolizumab 4nimotuzumab 3nedaplatin 3Radiotherapy 3Radiation 3Carboplatin 3toripalimab 2spartalizumab 2camrelizumab 2anlotinib 2Quality of Life 2Protons 2Paclitaxel 2Nivolumab 2Dexamethasone 2Chemoradiotherapy 2tislelizumab 1raltitrexed 1penpulimab 1icotinib 1fosaprepitant 1famitinib 1endostar protein 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Nasopharyngeal Carcinoma × famitinib × Clear all
NCT01392235 2019-01-22

Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Completed
58 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡